S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
LON:GSK

GSK - GSK Share Forecast, Price & News

GBX 1,437.80
-0.40 (-0.03%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
1,429
1,449
50-Day Range
1,376.60
1,502.60
52-Week Range
1,280.92
2,280.50
Volume
3.91 million shs
Average Volume
8.45 million shs
Market Capitalization
£58.81 billion
P/E Ratio
1,295.32
Dividend Yield
4.24%
Price Target
GBX 1,573.33

GSK MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
9.4% Upside
GBX 1,573.33 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.56
Upright™ Environmental Score
News Sentiment
0.36mentions of GSK in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
£42.49 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars


GSK stock logo

About GSK (LON:GSK) Stock

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Wave Life Sciences Ltd.; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

Schrodinger is an AI-Powered Drug Discovery Developer to Watch (GSK)
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
Jonathan Symonds Buys 2,100 Shares of GSK plc (LON:GSK) Stock
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
GSK (LON:GSK) Lifted to Buy at Deutsche Bank Aktiengesellschaft
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
What GSK Didn’t Say About Zantac for 40 Years
UPDATE 1-U.S. FDA approves GSK's anemia drug
GSK (GSK) Q4 Earnings and Revenues Top Estimates
GSK Plc Gets a Belated Fundamental Downgrade
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Last Earnings
7/29/2020
Ex-Dividend for 1/12 Dividend
11/17/2022
Dividend Payable
1/12/2023
Ex-Dividend for 4/13 Dividend
2/23/2023
Today
3/23/2023
Dividend Payable
4/13/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
90,096
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 1,573.33
High Stock Price Forecast
GBX 2,000
Low Stock Price Forecast
GBX 1,245
Forecasted Upside/Downside
+9.4%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
£4.46 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£29.32 billion
Cash Flow
GBX 176.62 per share
Book Value
GBX 263 per share

Miscellaneous

Outstanding Shares
4,090,000,000
Free Float
N/A
Market Cap
£58.84 billion
Optionable
Optionable
Beta
0.27

Key Executives

  • Ms. Emma Natasha Walmsley (Age 53)
    CEO & Director
    Comp: $3.88M
  • Mr. Iain James Mackay (Age 61)
    CFO & Exec. Director
    Comp: $2.88M
  • Ms. Julie Brown (Age 61)
    Chief Financial Officer
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Sr. VP & Group Gen. Counsel of Legal & Compliance
  • Ms. Sally Jackson
    Sr. VP of Global Communications & CEO Office
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. David Simon Redfern (Age 57)
    Chief Strategy Officer













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

What is GSK's stock price forecast for 2023?

8 equities research analysts have issued 12-month price targets for GSK's stock. Their GSK share price forecasts range from GBX 1,245 to GBX 2,000. On average, they anticipate the company's share price to reach GBX 1,573.33 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for GSK
or view top-rated stocks among Wall Street analysts.

How have GSK shares performed in 2023?

GSK's stock was trading at GBX 1,437.60 at the start of the year. Since then, GSK stock has increased by 0.1% and is now trading at GBX 1,438.60.
View the best growth stocks for 2023 here
.

How were GSK's earnings last quarter?

GSK plc (LON:GSK) posted its earnings results on Wednesday, July, 29th. The company reported $56.90 EPS for the quarter. GSK had a trailing twelve-month return on equity of 31.31% and a net margin of 51.00%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK declared a dividend on Wednesday, February 1st. Stockholders of record on Thursday, February 23rd will be paid a dividend of GBX 13.75 per share on Thursday, April 13th. This represents a dividend yield of 0.97%. The ex-dividend date is Thursday, February 23rd. The official announcement can be accessed at this link.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (LON:GSK) pays an annual dividend of GBX 61 per share and currently has a dividend yield of 4.43%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 5,495.50%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).

What is GSK's stock symbol?

GSK trades on the London Stock Exchange (LON) under the ticker symbol "GSK."

How do I buy shares of GSK?

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately GBX 1,438.60.

How much money does GSK make?

GSK (LON:GSK) has a market capitalization of £58.84 billion and generates £29.32 billion in revenue each year. The company earns £4.46 billion in net income (profit) each year or GBX 1.11 on an earnings per share basis.

How many employees does GSK have?

The company employs 90,096 workers across the globe.

How can I contact GSK?

GSK's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The official website for the company is www.gsk.com. The company can be reached via phone at +44-20-80475000.

This page (LON:GSK) was last updated on 3/23/2023 by MarketBeat.com Staff